Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.20 USD
Change Today -0.007 / -3.38%
Volume 57.0K
TPIV On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

tapimmune inc (TPIV) Snapshot

Open
$0.21
Previous Close
$0.21
Day High
$0.21
Day Low
$0.20
52 Week High
04/3/14 - $4.09
52 Week Low
02/13/15 - $0.12
Market Cap
6.5M
Average Volume 10 Days
100.4K
EPS TTM
$-1.80
Shares Outstanding
32.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAPIMMUNE INC (TPIV)

Related News

No related news articles were found.

tapimmune inc (TPIV) Related Businessweek News

No Related Businessweek News Found

tapimmune inc (TPIV) Details

TapImmune Inc., clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. It is involved in the development of HER2/neu, a vaccine technology, which is in Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which is in Phase I human clinical trials for the treatment of breast and ovarian cancer. The company’s products under preclinical stage include Polystart, a nucleic acid–based technology for Her2/neu breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. TapImmune Inc. has a technology option agreement with Mayo Foundation for the evaluation of HER2/neu peptide epitopes, as well as has a research license and option agreement with Crucell Holland B.V. The company was founded in 1999 and is based in Seattle, Washington.

2 Employees
Last Reported Date: 04/17/14
Founded in 1999

tapimmune inc (TPIV) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

tapimmune inc (TPIV) Key Developments

Tapimmune, Inc. Appoints David Laskow Pooley to the Company's Board of Directors

TapImmune Inc. announced the appointment of David Laskow-Pooley to the company's board of directors. David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and exiting start-up businesses, spin-outs from large corporations and business entities within large companies. Mr. Laskow-Pooley is currently CEO of London Pharma Ltd. He was formerly Managing Director (UK) of Nasdaq- listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech.

TapImmune Appoints Patrick D. Yeramian as Consulting Medical Director

TapImmune announced Patrick D. Yeramian, MD, MBA, has been appointed as Consulting Medical Director. He will lead TapImmune's clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies. These technologies have been evaluated in Phase I trials for safety and immune responses in women with breast or ovarian cancer. Dr. Yeramian has over 25 years of experience in the pharmaceutical industry. He has supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents, and vaccines as well as having held a prominent role in the approval of several new drug (metronidazole - Flagyl MR®), biological (interferon alpha - Multiferon, nafarelin – Synarel) and device (Inerpan) applications in the US in the EC and the granting of over 20 successful INDs and IMPDs. Dr. Yeramian is currently the Medical Director of the Vaccine and Gene Therapy Institute, Florida. Dr. Yeramian has been working with TapImmune to design and execute Phase II clinical programs. Duties include the design of clinical protocols, selection of clinical trial sites, recruitment of key opinion leaders as clinical advisors, and selection of external manufacturing and clinical resources.

TapImmune, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 12:30 PM

TapImmune, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 12:30 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPIV:US $0.20 USD -0.007

TPIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPIV.
View Industry Companies
 

Industry Analysis

TPIV

Industry Average

Valuation TPIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAPIMMUNE INC, please visit www.tapimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.